Literature DB >> 21610535

Effect of hemodilution on coagulation and recombinant factor VIIa efficacy in human blood in vitro.

Daniel N Darlington1, Angel V Delgado, Bijan S Kheirabadi, Chriselda G Fedyk, Michael R Scherer, Anthony E Pusateri, Charles E Wade, Andrew P Cap, John B Holcomb, Michael A Dubick.   

Abstract

BACKGROUND: This study evaluates the effect of hemodilution by various common resuscitation fluids, and the efficacy of activated recombinant factor VII (rFVIIa) on coagulation parameters in human blood in vitro.
METHODS: Samples from normal healthy volunteers (n = 9) were hemodiluted from 0% to 90% with normal saline, or 0%, 40%, 60%, and 80% with 5% albumin, Hespan, Hextend, normal saline, or lactated Ringer's, and incubated at 37°C ± 1°C for 30 minutes with and without rFVIIa (1.26 μg/mL).
RESULTS: There was a strong correlation between the dilution of hemoglobin (Hb), platelets, or fibrinogen and coagulation parameters. Hemodilution 0% to 90% changed coagulation parameters (prothrombin time [PT], activated partial thromboplastin time [aPTT], and thromboelastography) in an exponential fashion; the greatest changes occurred after hemodilution lowered Hb <6 mg/dL, platelet count < 100,000/mm(3), and fibrinogen concentration <200 mg/dL. PT and aPTT were significantly prolonged after 60% and 80% dilution for all fluids. Hemodilution of 60% and 80% significantly decreased clot strength (maximum amplitude) and the kinetics of clot development (α angle) and increased the clot formation time (K). Hemodilution with Hextend and Hespan decreased maximum amplitude and α angle >5% albumin, lactated Ringer's, or normal saline. rFVIIa significantly improved PT at 60% and 80% dilutions, and aPTT at 80% dilution. There was a significant effect of dilution, but not fluid type, on the efficacy of rFVIIa to change PT and aPTT, and the onset of clotting (R).
CONCLUSIONS: We have strong in vitro evidence that Hb <6 mg/dL, platelet count <100,000/mm(3), and fibrinogen concentration <200 mg/dL can be used as indexes of hemodilution-induced coagulopathy. This study also shows that Hextend and Hespan tend to decrease the clotting ability >5% albumin or the crystalloids. rFVIIa significantly decreased PT at all dilutions and aPTT at the highest dilution. The effectiveness of rFVIIa on PT and aPTT was significantly affected by the degree of dilution, but not by the type of fluid.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21610535     DOI: 10.1097/TA.0b013e318215178c

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  8 in total

1.  Viscoelastic measurements of platelet function, not fibrinogen function, predicts sensitivity to tissue-type plasminogen activator in trauma patients.

Authors:  H B Moore; E E Moore; M P Chapman; E Gonzalez; A L Slaughter; A P Morton; A D'Alessandro; K C Hansen; A Sauaia; A Banerjee; C C Silliman
Journal:  J Thromb Haemost       Date:  2015-09-22       Impact factor: 5.824

2.  In vitro and in vivo effects of hemodilution on kaolin-based activated clotting time predicted heparin requirement using a heparin dose-response technique.

Authors:  Junko Ichikawa; Satoshi Hagihira; Testu Mori; Mitsuharu Kodaka; Keiko Nishiyama; Makoto Ozaki; Makiko Komori
Journal:  J Anesth       Date:  2016-08-08       Impact factor: 2.078

3.  Effects of In vitro hemodilution, hypothermia and rFVIIa addition on coagulation in human blood.

Authors:  Daniel N Darlington; Igor Kremenevskiy; Anthony E Pusateri; Michael R Scherer; Chriselda G Fedyk; Bijan S Kheirabaldi; Angel V Delgado; Michael A Dubick
Journal:  Int J Burns Trauma       Date:  2012-03-15

Review 4.  Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy.

Authors:  Mark Walsh; Stephanie Fritz; Daniel Hake; Michael Son; Sarah Greve; Manar Jbara; Swetha Chitta; Braxton Fritz; Adam Miller; Mary K Bader; Jonathon McCollester; Sophia Binz; Alyson Liew-Spilger; Scott Thomas; Anton Crepinsek; Faisal Shariff; Victoria Ploplis; Francis J Castellino
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

5.  Can We Rely on the Activated Clotting Time to Measure Heparin Anticoagulation? A Clinical Evaluation of Two ACT Monitors.

Authors:  Samuel Nilsson; Micael Appelblad; Staffan Svenmarker
Journal:  J Extra Corpor Technol       Date:  2020-09

6.  Comparison of stress-hemoconcentration correction techniques for stress-induced coagulation.

Authors:  Anthony W Austin; Stephen M Patterson
Journal:  Biomed Res Int       Date:  2013-10-07       Impact factor: 3.411

7.  Association between fluid management and dilutional coagulopathy in severe postpartum haemorrhage: a nationwide retrospective cohort study.

Authors:  Ada Gillissen; Thomas van den Akker; Camila Caram-Deelder; Dacia D C A Henriquez; Kitty W M Bloemenkamp; Jos J M van Roosmalen; Jeroen Eikenboom; Johanna G van der Bom
Journal:  BMC Pregnancy Childbirth       Date:  2018-10-11       Impact factor: 3.007

8.  Preclinical evaluation of point-of-care prothrombin time as a biomarker test to guide prothrombin replacement therapy in coagulopathic bleeding.

Authors:  Clare A Balendran; Neil Henderson; Marita Olsson; Ann Lövgren; Kenny M Hansson
Journal:  Res Pract Thromb Haemost       Date:  2017-08-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.